Delving into the Latest Updates on Quadrivalent influenza virus vaccine (Eurocine Vaccines) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine

Synonyms

Immunose FLU

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Influenza, Human

Originator Organization

Eurocine Vaccines AB

Active Organization-

Inactive Organization

Eurocine Vaccines AB

Drug Highest PhasePendingPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Influenza virus infections pose a serious public health problem and vaccination is the most effective public health intervention against them. The current manufacture of influenza vaccines in embryonated chicken eggs entails significant limitations. These limitations have been overcome by producing vaccines in cell culture, which allow a faster and more flexible response to potential pandemic threats. Given the impact of influenza B virus on disease burden, the availability of quadrivalent vaccines is useful for increasing the rate of protection from disease. This paper analyzes the limitations of the current production of influenza vaccine in eggs and the advantages of vaccines developed in cell culture, as well as their safety, tolerability, efficacy and effectiveness. Additionally, we reflect on the contribution of new quadrivalent vaccines from cell culture as an alternative in seasonal vaccination campaigns against influenza.

100 Deals associated with Quadrivalent influenza virus vaccine (Eurocine Vaccines)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 2	Sweden	Eurocine Vaccines AB	01 Sep 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02998996 (CTgov)	Phase 1/2	Influenza, Human	162	15 µg HA/strain and 1% Endocine™ (Immunose™ FLU 1%,)	hoyshsffte(ykafnzpwee) = fvgsypkqeb gsnquoalmz (zqzjybkxro, dzlmazahyn - lbuijsmaxt) View more	-	21 Feb 2019
				15 µg HA/strain and 2% Endocine™ (Immunose™ FLU 2%,)	hoyshsffte(ykafnzpwee) = jtqehnvbsy gsnquoalmz (zqzjybkxro, gaigqhidfx - kqkpxvgsce) View more